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Abstract 
 
Diabetic retinopathy (DR) is more prevalent in blacks than whites because, compared to whites, 
blacks have worse glycemic control.  Both of these racial disparities reflect differences in sociocultural 
determinants of health, including physician mistrust..  This pilot randomized controlled 6-month trial 
compared the efficacy of a culturally tailored behavioral health/ophthalmologic intervention, 
Collaborative Care for Depression and Diabetic Retinopathy (CC-DDR), versus Enhanced Usual Care 
(EUC), to improve glycemic control in blacks with DR (N=33).  The mean age of participants was 68 
years (SD 6.1); 76% were women; and mean hemoglobin A1c level (HbA1c) was 8.7 (1.5).  At 
baseline, 14 participants (42%) expressed mistrust about ophthalmologic diagnoses. After 6 months, 
CC-DDR participants had a clinically meaningful decline in HbA1 of 0.6 (SD 2.1), whereas EUC 
participants had an increase of 0.2 (SD 1.1); [f (1,28) = 1.9; p = .176].  Within CC-DDR, participants 
with trust had a reduction in HbA1c [1.4 (2.5)], whereas participants with mistrust had an increase in 
HbA1c [0.44 (0.7)]; f (1, 11) = 2.11; p = .177].  EUC participants with trust had a reduction in HbA1c 
[0.1 (1.1)] whereas those with mistrust had an increase in HbA1c [0.70 (1.1)]; f (1,16) = 2.01; p = 
.172]. Mistrust adversely affected glycemic control independent of treatment.  This finding, coupled 
with the high rate of mistrust, highlights the need to target mistrust in new interventions to improve 
glycemic control in blacks with DR.  
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Rates of diabetic retinopathy (DR) and uncontrolled diabetes are higher in blacks than whites in the 
United States..1, 2  Both of these racial disparities reflect differences in sociocultural determinants of 
health, including physician mistrust.3  Mistrust arises when patients doubt physicians’ motivations 
(e.g., conflicts of interest), when patient and physician understanding of symptoms and treatment are 
discordant, and when patient low health literacy encounters physician cultural insensitivity to degrade 
the therapeutic relationship.  As an example of the latter, blacks cite problems with trust and 
communication with eye doctors as obstacles to care, whereas eye doctors cite blacks’ lack of 
understanding of treatment.4  This mismatch contributes to poor glycemic control - blacks with poorly 
controlled diabetes are more likely to report negative healthcare experiences than whites.5  These 
data implicate mistrust as an important determinant of racial health disparities, and suggest that 
culturally relevant interventions may help to achieve health equity.   
 
We developed a culturally tailored behavioral health/ophthalmologic intervention, Collaborative Care 
for Depression and Diabetic Retinopathy (CC-DDR), to improve glycemic control in blacks with DR, 
and compared its effectiveness with Enhanced Usual Care (EUC) in a pilot single-masked, 
randomized controlled trial.  In CC-DDR, race-concordant community health workers (CHWs) 
provided health information [e.g., hemoglobin A1c (HbA1c) level, diabetes self-care] to 
ophthalmologists to guide their discussions with participants on glycemic control, and delivered 6 in-
home treatment sessions to participants to develop goals and action plans to improve glycemic 
control.  EUC was usual ophthalmologic care plus the provision of diabetes educational materials at 
baseline.  Here we report treatment effects on glycemic control and the influence of mistrust. 
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Methods 
 
CHWs recruited participants from the retina clinic of Wills Eye Hospital, Philadelphia, PA, who met the 
following eligibility criteria: 1) African-American race; 2) age ≥ 65 years; 3) type 2 diabetes; 4) mild or 
moderate nonproliferative DR; 5) depressive symptoms (i.e., Patient Health Questionnaire-9 score 
≥5)6; and 6)HbA1C ≥ 7.0%.  Institutional review board approval was obtained and all participants 
provided written informed consent.  The CHWs received training to conduct clinical assessments and 
deliver the study interventions.  They received 15 hours of didactic and skills-based training on 
diabetes, DR, and lifestyle strategies for glycemic control, and 4 hours on interviewing and supportive 
psychological techniques (e.g., empathy), managing time, and gathering research-quality data. 
Training for the CHWs who delivered CC-DDR consisted of a daylong workshop, including readings 
and supervised role-play, and supervision of 5 training cases. The investigators met twice a month  
with the CHWs to discuss ongoing cases.  To maintain treatment masking, different CHWs collected 
follow-up data and delivered the intervention. 
 
Prior to randomization, a CHW used a standardized protocol to assess the following variables: 
 
     Personal Characteristics: Collected data included age, sex, education, marital status, duration and 
type of diabetes , socioeconomic status, and health literacy (using the Literacy Assessment for 
Diabetes, which tests pronunciation of diabetes-related terms).7 
     DR stage and Visual Acuity:   These data were abstracted from medical records. DR was staged 
as background, mild, moderate or severe nonproliferative disease, proliferative, or indeterminate.  
Visual acuity was based on Snellen charts, which was converted to the logarithm of the minimum 
angle of resolution (logMAR) scores to facilitate statistical analyses. 
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     Trust:  A single item tapping trust in ophthalmologists’ diagnoses (i.e., “Sometimes eye doctors 
make me wonder if their diagnosis is correct.”) was taken from the Duke Eye Clinics Patient 
Satisfaction Questionnaire, and rated as strongly agree, agree, uncertain, disagree, or strongly 
disagree.8  Mistrust was considered present if a participant agreed or strongly agreed with the 
statement. 
     Diabetes Self-Care:  The Diabetes Self-Care Inventory-Revised was used to assess self-reported 
adherence to 12 diabetes self-care behaviors (e.g., glucose monitoring, exercise, diet).  Items are 
rated on a 5-point Likert scale (i.e., 1 = “never do this” to 5 = “always do this”).  Scores range from 0 
to 100; higher scores indicate better adherence.9     
     Depressive Symptoms:  The Patient Health Questionnaire-9 was used to assess depression.  This 
instrument yields a continuous measure of symptoms and has known reliability and validity in older 
blacks.6, 10   Scores range from 0 to 27, with higher scores indicating worse depression.   
     Functional Vision:  The 39-item National Eye Institute Visual Function Questionnaire plus 
Supplement (NEI VFQ) was used to assess difficulty with vision-related activities, social functioning, 
mental health, role difficulties, and dependency. Scores range from 0 to 100; higher scores indicate 
better function.11 
     Hemoglobin A1c (HbA1c) [Primary Outcome]: HbA1c level represents glycemic control over the 
preceding 3 months and provides a valid surrogate marker of DR progression.12  The CHWs used the 
DCA Vantage point-of-care device per study protocol to measure HbA1c at baseline and 6 months 
masked to treatment assignment.  The CHW who delivered CC-DDR provided the result to the 
ophthalmologist to inform their care of the patient. 
 
Statistical Methods:  Continuous and categorical data were analyzed using one-way analysis of 
variance (ANOVA) and chi-square, respectively. To determine if trust moderated treatment effects, a 
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2 (CC-DDR vs. EUC) X 2 (trust vs. mistrust) ANOVA was computed in which change in HbA1c level 
was the dependent variable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
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Thirty-three participants with complete data were recruited and randomized to CC-DDR (n=16) or 
EUC (n=17).  Their mean age was 68 years (SD 6.1); 76% were women. The mean HbA1c level was 
8.7 (1.5). There were no treatment group differences at baseline in any study variable (data not 
shown). Fourteen participants (42%) expressed mistrust about their ophthalmologic diagnoses. Table 
1 shows that the demographic and clinical characteristics of participants with and without trust did not 
differ significantly.  
 
Four participants (3 CC-DDR; 1 EUC) withdrew from the study protocol by 6 months (2 with mistrust).  
Table 2 shows treatment group differences in HbA1c level over time, and treatment group differences 
by trust.  CC-DDR participants had a clinically meaningful decline in HbA1c of 0.60 (SD 2.1), whereas 
EUC participants had an increase of 0.20 (SD 1.10); [f (1,28) = 1.90; p = .176].  Within CC-DDR, 
participants with trust had a reduction in HbA1c [1.40 (2.50)], whereas participants with mistrust had 
an increase in HbA1c [0.44 (0.70)]; f (1, 11) = 2.11; p = .177].  EUC participants with trust had a 
reduction in HbA1c [0.10 (1.10)] whereas those with mistrust had an increase in HbA1c [0.70 (1.10)]; f 
(1,16) = 2.01; p = .172].  Table 2 also shows a statistically significant main effect for trust.  This 
finding indicates that mistrust adversely affected glycemic control independent of treatment effects. 
 
 
 
 
 
Discussion 
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This pilot clinical trial suggests that a CHW-ophthalmologist intervention that is culturally relevant to 
blacks with DR can improve glycemic control to a greater extent than usual care that is enhanced with 
diabetes educational materials.  Neither treatment, however, improved glycemic control in participants 
who mistrusted their ophthalmologic diagnosis.  These participants doubted the accuracy and veracity 
of ophthalmologists’ diagnoses; some participants believed that ophthalmologists wanted them to 
take more medications so that doctors and pharmacies could make more money.  In general, if a 
patient doubts that diabetes has damaged their eyes and mistrusts the goals of treatment, they are 
unlikely to perceive the need to control their diabetes.  This perception is important because 42% of 
participants held this view, and their glycemic control worsened over time regardless of treatment.   
 
These findings are limited by the small sample size, short duration of follow-up, the absence of 
information that might relate to study outcomes (e.g., type of diabetes care provider and prescribed 
medications, prior work with a diabetes educator, living arrangements, and anthropomorphic data), 
and the uncertain psychometric properties (i.e., reliability and validity) of a single item assessing trust 
in the diagnosis of DR.    Nevertheless, the high rate of mistrust is notable, and is similar to the 44.7% 
rate of low trust in physicians reported by blacks (vs. 33.5% in whites) in a national study of race, 
ethnicity, and medical care in the United States.13 
 
Trust in physicians depends on appreciating patients’ knowledge, beliefs, and attitudes and, for 
blacks in particular, on perceived racism.14  The latter predicts lower rates of physician visits, 
medication adherence, and preventive care, which compromise glycemic control and increase risk for 
progression of DR to blindness.15  Because blindness is the most feared complication of diabetes, 
ophthalmologists have the opportunity to collaborate with other diabetes health professionals to 
emphasize the importance of glycemic control to prevent vision loss.  Mistrust, however, undercuts 
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that opportunity, as does a lack of time, expertise, and resources available to ophthalmologists to 
address this problem.  
 
We devised and tested a retina clinic-to-community intervention to improve glycemic control in blacks 
with DR.  Although the small sample size precludes definitive conclusions, this pilot study suggests 
that the experimental intervention, , despite its cultural relevance, failed to improve glycemia in 
participants with mistrust.  For this reason, these participants remain at  increased  risk for  
progressive vision loss.  By contrast, preserving vision can prevent medication errors and reduce 
hospitalizations and the considerable costs of vision loss.16-18  These benefits are relevant to new 
outcomes-based reimbursement strategies in which ophthalmologists, as well as primary care 
providers (e.g., physicians, physician assistants, and nurse practitioners) , will be responsible for 
vision outcomes.  Our data highlight the need to target mistrust in interprofessional collaborative 
clinical interventions that aim to improve glycemic control in blacks with DR.  Larger studies are 
needed to establish the efficacy and cost-effectiveness of this approach, which may improve care 
quality and prevent progressive vision loss. 
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Table 1.  Baseline Characteristics of Participants with High and Low Trust  
 High Trust 
(n = 19) 
Low Trust 
(n = 14) 
p 
Age (mean, SD) 66.8 (3.7) 69.9 (8.2) .165 
Education (mean, SD) 12.4 (2.2) 12.0 (3.4) .707 
Female (n, %) 14 (74%) 11 (79%) .746 
Hemoglobin A1c (mean , SD) 8.8 (1.8) 8.6 (1.1) .703 
PHQ-9 (mean, SD)1 10.2 (4.5) 10.2 (5.1) .993 
MoCA (mean, SD)2 22.7 (3.7) 20.7 (4.2) .152 
DSCI (mean, SD)3 55.9 (14.1) 59.4 (11.7) .448 
LogMAR (mean, SD)4 .16 (.16) .20 (.15) .532 
NEI-VFQ total score (mean, SD)5 73.1 (17.3) 75.6 (18.9) .693 
 
1  Patient Health Questionnaire; range is 0 to 27; higher scores indicate more severe depressive 
symptoms. 
2 Montreal Cognitive Assessment; range is 0 to 30; higher scores indicate better cognitive function. 
3 Diabetes Self-Care Inventory; range is 0 to 100, higher scores indicate better adherence to diabetes 
self-care behaviors. 
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4 Best eye visual acuity expressed as the logarithm of the minimum angle of resolution; higher scores 
indicate worse visual acuity. 
5 National Eye Institute Visual Function Questionnaire; range is 0 to 100; higher scores indicate better 
self-reported vision function. 
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Table 2:  Two (CC-DDR1 vs. EUC2) by Two (Trust vs. Mistrust) ANOVA of Change in Hemoglobin 
A1c from Baseline to 6 Months3   
 N Baseline 6 Months Mean 
Change4 
F p 
CC-DDR, total group: 
   Trust subgroup 
   Mistrust subgroup 
12 
7 
5 
8.7 (2.1) 
 9.1 (2.7) 
  8.2 (1.1) 
8.1 (.9) 
7.7 (.8) 
8.5 (.9) 
- 0.6 (2.1) 
- 1.4 (2.5) 
0.36 (0.7) 
  
Enhanced Usual Care, total group 
   Trust subgroup 
   Mistrust subgroup 
17 
10 
7 
8.5 (.9) 
  8.5 (1.0) 
8.4 (0.8) 
   8.7 (1.6) 
   8.4 (1.8) 
   9.1 (1.2) 
 0.2 (1.1) 
- 0.1 (1.1) 
0.7 (1.1) 
  
______________________________ 
Main effect of treatment group 
     
1.7 
 
.202 
Main effect of trust group     4.5 .044 
Treatment by trust interaction     0.6 .441 
1 Collaborative Care for Depression and Diabetic Retinopathy 
2 Enhanced Usual Care 
3 Numbers shown are means.  Standard deviations are in parentheses. 
4 6 months minus baseline; a negative sign represents improved glycemic control. 
 
